Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart patients may get kidney protection from common diabetes pills

NCT ID NCT06491953

Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether SGLT-2 inhibitors, a type of diabetes medication, can prevent kidney damage from contrast dye used during heart procedures like angioplasty. Researchers will follow 3,600 adults with acute coronary syndrome who are undergoing invasive treatment. The goal is to see if these drugs reduce the risk of acute kidney injury after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT-2 inhibitors (a class of diabetes drugs that help protect the kidneys and heart)
What this could lead to
If successful, this could show that SGLT-2 inhibitors help prevent kidney injury caused by contrast dye in heart patients, offering a new protective use for these drugs.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Early use of SGLT-2 inhibitors can temporarily reduce kidney function, which might increase risk in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

ACS patients aged 18-80 years old receiving invasive treatment were enrolled.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ACS patients undergoing invasive treatment (PCI or CAG) * 18 \~ 80 years old adult patients * Written informed consent provided Exclusion Criteria: * Administration of any iodinated CM within 14 days before CAG or PCI * Hepatic dysfunction (ALT 3 times greater than upper normal limit) * Thyreoid insufficiency * Renal artery Stenosis (unilateral \>70％ or bilateral stenosis\>50％) * Known allergy to any of the study drugs or devices (iodinated CM, etc.) * Pregnancy or lactation * Contraindications for the use of SGLT-2 inhibitors, such as severe renal insufficiency (eGFR \<30 mL/min/1.73m2 or currently on dialysis), type 1 diabetes mellitus, severe infection, etc.) * Any condition which might interfere with study compliance, or otherwise unsuitable for study participation as judged by the investigators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Impact of SGLT2-inhibitors on PC-AKI in acs patients receiving invasive strategy

Contacts and locations

Locations

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.